A technical file assembled just before an ARTG application often exposes issues that began much earlier: an intended purpose that does not match the clinical evidence, risk controls that are not reflected in the instructions for use, or a manufacturer document that cannot support the Australian supply model. Knowing how to prepare TGA technical documentation means building a connected evidence base, not simply collecting certificates and reports.
For manufacturers, sponsors and commercial teams, this work protects more than a submission timeline. It provides the evidence needed to support lawful supply, respond confidently to TGA requests and manage the device through post-market changes.
Start with the Australian regulatory pathway
Technical documentation should be planned around the device’s Australian classification, intended purpose and route to market. These decisions determine the depth of evidence required, the applicable conformity assessment pathway and the information that must support inclusion in the Australian Register of Therapeutic Goods (ARTG).
Begin by documenting the product precisely. Define what it is, who will use it, the patient population, clinical setting, duration of use, whether it is invasive or active, and every claimed indication. The intended purpose should be consistent across the label, instructions for use, promotional material, risk management file, clinical evidence and declaration of conformity. Small differences in wording can create a material regulatory issue.
Classification is not a commercial preference. It follows the applicable TGA classification rules and depends on the device’s characteristics and intended use. A software device, reusable surgical instrument, implantable device and in vitro diagnostic (IVD) each require a different evidence focus. Where classification or classification rule application is uncertain, resolve it before commissioning studies or finalising labels. Rework at this stage is far less costly than changing a dossier late in the process.
How to prepare TGA technical documentation around evidence
There is no benefit in producing a large file that a reviewer cannot navigate. The most effective documentation follows a clear structure, uses controlled versions and allows each claim to be traced to objective evidence.
A practical technical documentation set commonly includes the following connected elements:
- a device description, including variants, accessories, components, materials and intended purpose;
- classification rationale and regulatory pathway assessment;
- design and manufacturing information, including critical suppliers and processes where relevant;
- a risk management file aligned with ISO 14971 principles;
- evidence of compliance with the Essential Principles for safety and performance;
- verification and validation evidence, such as biocompatibility, electrical safety, electromagnetic compatibility, software validation, usability, sterility or packaging validation, as applicable;
- clinical evaluation or performance evidence, including literature, clinical investigation data and post-market information where appropriate;
- labelling, instructions for use and advertising claim controls;
- quality management system and conformity assessment evidence; and
- a declaration of conformity, supported by the correct manufacturer and device details.
Not every device needs every test listed above. A non-sterile, low-risk device will not have the same testing profile as a sterile implant or connected diagnostic platform. The principle is straightforward: each identified risk and each performance claim must have evidence proportionate to the device and its use.
Build an Essential Principles checklist early
The Essential Principles are central to demonstrating that a medical device is safe and performs as intended. Rather than treating them as a final administrative checklist, use them to guide development and evidence planning.
For each applicable principle, identify the supporting document, its version, the relevant section and any limitation. A traceability matrix is particularly useful because it shows how risk controls, test reports, clinical evidence and labelling work together. For example, if the instructions for use direct a clinician to inspect a component before use, the risk file should explain why that control is needed and the verification evidence should support its effectiveness.
Generic statements such as “complies with relevant standards” are rarely enough on their own. Identify the applicable standards, confirm the version used, explain any deviations and retain the underlying reports. Where a standard has been partly applied, the rationale and alternative evidence should be clear.
Treat clinical evidence as a claim-by-claim exercise
Clinical evidence is often the critical path, particularly for higher-risk devices, novel technologies and devices with broad therapeutic claims. The clinical evaluation should assess whether the available evidence supports safety, clinical performance and the intended purpose of the specific device.
Equivalence to another device can sometimes contribute to the evidence base, but it must be justified with meaningful access to comparable technical, biological and clinical information. A similar-looking product, a competitor brochure or a published study on a related technology is not automatically sufficient.
The appropriate level of clinical evidence depends on the device, its risk profile, novelty, clinical claims and existing post-market history. For IVDs, performance evaluation must similarly address scientific validity, analytical performance and clinical performance. Teams should avoid leaving this assessment until all other documentation is complete, as evidence gaps can affect product claims, launch dates and the viability of the chosen pathway.
Align Australian labelling with the evidence file
Labelling is not separate from technical documentation. It is where many of the file’s conclusions become operational for users, patients and distributors.
Review labels and instructions for use against the final intended purpose, contraindications, warnings, precautions, residual risks and storage conditions. Ensure the Australian sponsor details are correctly included where required and that the supplied information is appropriate for the intended Australian user. If the device is supplied in multiple configurations, confirm that each configuration is represented accurately.
Commercial teams should also control website copy, product sheets and sales presentations. Promotional claims that go beyond the intended purpose or clinical evidence can undermine the regulatory position, even if the formal instructions for use are well written. A disciplined claim review process keeps market messaging aligned with the documentation supporting ARTG inclusion.
Establish ownership between manufacturer and sponsor
For overseas manufacturers, the Australian sponsor has important responsibilities after market entry, including maintaining records, supporting vigilance activities and responding to the TGA. The sponsor therefore needs reliable access to current technical documentation and a defined process for receiving updates.
This does not necessarily mean transferring every proprietary manufacturing record to the sponsor. It does mean agreeing, before supply begins, who holds each document, how quickly it can be provided, who assesses changes and when the sponsor must be notified. The arrangement should cover design changes, supplier changes, new clinical data, complaints, recalls, field safety corrective actions and revised certificates.
A strong document access arrangement is commercially sensible as well as compliant. When a regulator asks a question, uncertainty over ownership can turn a manageable request into a time-sensitive escalation.
Make the file inspection-ready, not submission-only
Technical documentation must remain current throughout the device lifecycle. Establish document control, approval responsibilities, revision history and review triggers within the quality management system. A well-organised electronic dossier should allow a regulatory manager or sponsor to find the current approved document without relying on informal email trails.
Before ARTG inclusion, conduct a focused gap assessment. Test whether the device name, model list, classification, intended purpose, manufacturer details and conformity assessment evidence are consistent across all core records. Check that reports are complete, signed where required, applicable to the final device configuration and not superseded by later design changes.
It is also sensible to rehearse a regulator request. Ask whether the team could provide the classification rationale, Essential Principles matrix, risk file, clinical evidence and current labelling promptly, with a clear explanation of how they connect. If the answer is no, the documentation is not yet ready.
For businesses balancing product development, international approvals and a planned Australian launch, independent regulatory review can bring valuable clarity. Compliance Management Solutions (C|M|S) helps manufacturers and sponsors assess evidence gaps, coordinate technical documentation and establish a practical route to compliant market entry.
The strongest file is not the one with the most pages. It is the one that gives a clear, evidence-based answer to a simple question: why should this device be supplied in Australia, for this intended purpose, with these controls in place?